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Q&ATrends in Precision Medicine:
An Interview with UCSF’s Atul ButteAtul Butte, Director of the Institute for
Computational Health Sciences at the
University of California San Francisco, is a
few months into a new tenure aimed at
harnessing clinical, environmental, and
genomic data to improve healthcare and
do basic research. He’s not alone.
In September, a committee formed by
the NIH outlined the design and utility of a
cohort of 1 million or more Americans
to ‘‘expand our knowledge and practice
of precision medicine’’ (http://www.
nih.gov/precisionmedicine/09172015-pmi-
working-group-report.pdf). The commit-
tee cites three factors—proliferation of
electronic health records; cost-effective
profilingofDNAandmetabolites; andubiq-
uitous mobile, wearable devices—that
have set the stage for new opportunities
to understand why disease happens and
what can be done about it.
I spoke with Butte to discuss the forces
that will shape precision medicine in the
coming years. He talked about using
data from large clinical cohorts for good
basic science, as well as clinical care,
and the aspects of biological research
that will never be outsourced. An edited
transcript of the conversation follows.
Cell Systems: What keeps you up at
night?
Atul Butte: I think if you ask the people in
my lab, especially the senior folks, they
would tell you 99% of the hard part of the
work we do in my lab is figuring out what’s
the question we want to ask. I keep telling
people this all the time: we’ve got the
data and we’ve got the computational
methods. In my lab, we know how to
code up new ones. But what do we want
to use it all for? That is the hard part.
Computational investigators like us have
to attend medical seminars and biological
seminars and hear what is the unmet
need. There’s still so much unmet need
in medicine, needing our attention.
Is that why there’s so much
excitement behind precision
medicine?
Exactly. I think precision medicine right
now is a buzzword because it seems like254 Cell Systems 1, October 28, 2015 ª2015it could have a lot of impact for patients.
But it really still has to be defined and
proven.
Speaking of definitions. What’s the
difference between precision
medicine and systems medicine?
Precisionmedicine is the customization of
health care for the individual, given the
biological, behavioral, and environmental
measurements we can make for that indi-
vidual, given what we have learned from
similar measurements across the popula-
tion, and given our past experiences in
caring for patients. Precision medicine
has a lot of data science in it, but it’s not
exclusively data science. Precision medi-
cine might involve biological testing—for
example, a million compounds in a chem-
ical library that are tested on a thousand
cell lines or patient-derived tumors.
There’s a lot of biology in that example
experiment, and these new approaches
to biology certainly generate a lot of
data. But there are other ways to think
about precision medicine beyond just
the data aspect. Systems medicine, to
me, is a lot more data-driven. It might be
molecular, but there are other bigger sys-
tems at play, like payers and public health
needs. It’s a lot more particular about the
pieces, the components, how information
is exchanged between components.
But overall, I tend not to obsess over
definitions. I hate discussions over termsElsevier Inc.like these. I think there are lumpers and
there are splitters, as has been said, and
I tend to be a lumper, not a splitter, putting
these kinds of approaches together.
What trends do you see shaping
precision medicine?
I think one trend I am seeing is the idea
that the larger cohorts that one can get
organized under study, the better and
more impactful the findings are going to
be in the future. I see this reflected across
the country, where we can see more
health systems organizing their patient
populations and partnering with others
to make larger cohorts. These health sys-
tems are starting to engage their popula-
tion more, getting them more involved in
research, collecting their samples, and
now making molecular measurements
on these cohorts. Of course the NIH is
trying to build a cohort of a million volun-
teers as well. I see more drugs and diag-
nostics for precision medicine coming
from research on these cohorts.
How are different institutions using
large patient cohorts?
Some are getting genomics done, such as
genotyping the individuals. Many are
trying to get their electronic health records
organized. In themedical field,we’vebeen
collecting a lot of medical and physiolog-
ical data on patients for a long time, but
we typically don’t use electronic health
record data for science, especially basic
science. Even though these are human
physiological measurements, and we re-
cord everything we do to these patients,
we rarely use EHR [electronic health re-
cord] data for actual science. I think that’s
going to change a lot in the next couple of
years across these cohorts.
What other trends are you seeing?
I also see the growing recognition of
the importance of non-genomic factors
in precision medicine. In particular, the
study of behaviors and environment are
going to be critical. As a trivial example,
we might have genome sequences on
our patients, we might even have patients
that can afford their meds and have
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Q&Apatients that are no longer living next to
pollutants, but if we in medicine don’t
practice quality medicine, the whole thing
falls apart. I see all of this coming
together. The quality care people rarely
talk to the genomics people. And these
two rarely talk to the environmental scien-
tists. But all three are really actually work-
ing to determine and reach the best
outcomes for patients. I see that conflu-
ence happening in all three fields.
Are you thinking about mobile
devices in healthcare?
Mobile health comes in lots of different
flavors. Use of the mobile device as a
therapeutic or as an intervention is key
milestone we need to reach. Of course
mobile devices are also useful for data
collection from patients when they’re
well or when they’re sick, and those
measurements are important for clinical
research. Along this way, UCSF has
recently launched the PRIDEStudy,which
uses Apple ResearchKit. It’s featured by
Apple right now in the app store. At
UCSF we also have the Center for Digital
Health Innovation, CDHI, which has been
doing strong work for years before I got
here. They had a partnership already
announced with Samsung, and they’re
trying to build a core infrastructure for
getting mobile data into clinical data re-
positories. More recently, Jeff Olgin at
UCSF received a new major award from
the NIH for scaling up his Health eHeart
study to include new studies enabled by
this mobile approach.
Are you still interested in using
companies to outsource wet bench
work?
So we’re definitely using those kinds of
companies and just to give a disclaimer,
I’m a scientific advisor to Assay Depot.
Are those companies picking up steam?
It seems like they are. They’re certainly
being discussed more often, and there
are newer activities, such as Mousera.
com or Transcriptic.com, where you can
outsource biological experiments or syn-
thetic biology or the creation of primers.
Importantly, outsourcing experiments
to ‘‘neutral’’ professionals is now seenas a possible remedy for the reproduc-
ibility challenge facing academia. A lot
of kinds of experiments can be out-
sourced now, especially for those types
of experiments that have high demand.
Vendors are looking at the economies
of scale. I don’t see that many com-
panies trying to offer everything. They’re
trying to be really good at one or two or
three things. You also have crowd-
funding platforms, such as Indiegogo.
com, Kickstarter.com, and Experiment.
com, that are also enabling citizen-scien-
tist initiation of experiments that could
benefit from these kinds of companies
and resources.
Is this something you think that
academics need to pay attention to?
Yes, they should, but they aren’t yet. In
fact, in some ways, the computational-
based researcher really should take
advantage of these, because, like my lab,
they usually have no access to direct bio-
logical experiments except through col-
laborators. I can’t really say its use in
academia has exploded yet, though. I
think that we still have this kind of belief
that people believe that they have to run
as many components of the experiment
as they can themselves, and that probably
slows us down and leads to inefficiencies.
But I see someof it happening. Theearliest
manifestation of outsourcing is core facil-
ities. I think core facilities are typically are
kind of the canary, the earliest marker for
where science is going in academia. For
example, I see people using core facilities
all the time, but they rarely use another
institution’s core facilities. They often
use their own institutions’ core facilities.
ScienceExchange.com is trying to change
that behavior. But overall, I think it’s still
early.
What are the implications of this for
the individual researcher?
One of the things I do tell people is that it’s
really easy to be really good at a skill in
science and then, all of the sudden, that
skill is outsourced. Fifteen years ago,
when I startedwithmicroarray experiment
data analysis, right away, my mentor
Isaac Kohane said, ‘‘You can’t just beCell Systems 1the microarray person. You can’t even
just be themethods person there because
the field will move on. You’ve got to be
thinking more broadly than just being the
one microarray guy.’’ So one of the things
I do try to tell people, especially junior sci-
entists, is, ‘‘You can never outsource
asking good questions.’’ If you want to
go far in science, you better learn how to
ask good, important, tractable, significant
questions and come up with a strategy to
keep coming up with good questions
because asking good questions is just
going to be the last thing, if ever, to be out-
sourced in science.
In precision medicine, we have a wide-
open space, and if I have any piece of
advice, it’s really go after the unmet
need. If you go after that unmet need in
medicine and you come up with a solu-
tion, people appreciate it.
Any suggestions for where to look
for interesting questions?
A lot of computational biologists and
computational health scientists actually
work in a medical center, but they don’t
really know it. What I would tell people is
to take full advantage of being in amedical
center. I’ll give an example. Most
academic medical centers have some-
thing called grand rounds. Usually every
department runs one of these grand
rounds each week, and they’re inviting an
expert to come in. Yes, they’re run very
early in the morning, but you get an expert
that comes in and talks about a disease
area and tells the listener what is the very
state-of-the-art in that field, what’s known
about this disease area, and then they’re
telling you what’s left to discover.
These experts tell you ‘‘we need this,’’
and ‘‘we still can’t do this,’’ and ‘‘this is
where patients are dying,’’ and they do
this weekly for you in academic medical
centers, for free! Any computational sci-
entists and basic biologists that are next
to a big hospital or medical center have
got to take advantage of that! Go to grand
rounds and learn from people who are the
experts: what is the unmet need? Don’t
pretend you know it. Just go see what
the unmet need is, and that’s the way to
get started.
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